ClinicalTrials.gg
Status unknownNCT05664152Updated Dec 23, 2022

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

An interventional study of MG1111 in Varicella Zoster Virus Infection, sponsored by GC Biopharma Corp. Status unknown. Open to participants aged 12 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-23.

Primary conditionChickenpoxRegistry: Varicella Zoster Virus InfectionReclassifiedWhy we changed it
Registry
Varicella Zoster Virus Infection — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chickenpox
Why
  1. The study's listed conditions name Chickenpox, a narrower term within Varicella Zoster Virus Infection.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GC Biopharma Corp · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
12 Months to 12 Years
Sex
All
01

Study summary

The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are:

  • Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection)
  • Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection)

Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).

02

Conditions studied

  • Varicella Zoster Virus Infection

Browse trials for

Keywords

  • MG1111
  • Varicella
03

In context

Chickenpox Reclassified

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

This study's planned enrollment of 250 is below the median of 475 across 149 interventional studies indexed under Chickenpox.

Browse Chickenpox studies →

Lead sponsor

GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Compared within Chickenpox, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Varicella Zoster Virus Infection. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy children aged 12 months to 12 years (inclusive)
  2. Subject parent/legal representative willing to provide written and able to comply with the requirements for the study - Subject able to attend all scheduled visits and to comply with all study procedures
  3. Negative history of Varicella and varicella vaccine
  4. Subject in good health, based on medical history and physical examination
  5. Having a readily identifiable place of residence in the study area, being available for the duration of trial participation, with means of telephone contact.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a history of Varicella or administration of varicella vaccine
  2. Subjects who have reactions to the component of this Product, such as gelatin
  3. Subjects with untreated active tuberculosis
  4. Subjects with a history of Guillain-Barre syndrome
  5. Subjects who had received salicylates (aspirin, bismuth subsalicylates) within 4 weeks before administration of investigational product or those who are planning to receive salicylates within 42 days after administration of investigational drug.
  6. Subjects who administered anti-viral drug within 4 weeks before administration of investigational product or those who are planning to receive anti-viral drug within 42 days after administration of investigational drug.
  7. Subjects who have had an acute febrile episode (at least 38.00C) at some time during the 72 hours before administration of investigational product or those who had any symptom suspected to be allergy including systemic rash.
  8. Currently receiving or received any investigational intervention within 30 days prior to the vaccination of study vaccine.
  9. Subjects who have completed vaccinations within 4 weeks before enrolment or who are planning to administer other vaccines within 42 days after administration of investigational product.
  10. Administered any blood product or intravenous immunoglobulin administration within 44 weeks prior to the vaccination of study intervention
  11. Currently receiving or anticipate to receive concomitant or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing , low-dose methotrexate, or \< 2 weeks of daily receipt of prednisone less than 20 mg for subjects who weight more than 10kg and less than 2mg/kg/day for subjects who weight less than 10kg, or equivalent) within 12 weeks prior to the vaccination of study vaccine.
  12. Immunosuppressive illness or immunodeficient state, including hematologic , history of solid organ, bone marrow transplantation, or asplenia.
  13. Subject with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.
  14. Subjects with a severe chronic disease or other medical or psychological condition who are considered by the Investigator to be ineligible for the study.
  15. Subjects who are pregnant or lactating at the day of screening.
  16. Subjects who are planned to participate in another clinical trial during the present trial period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    MG1111

    Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).

    Biological: MG1111

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of BARYCELA inj.: Solicited local and systemic reactogenicity

    The incidence and severity of immediate solicited local and systemic reactogenicity

    Time frame: within 30-minute post vaccination

  2. Safety of BARYCELA inj.: The incidence and severity of solicited local and systemic AEs

    The incidence and severity of solicited local and systemic AEs

    Time frame: during 7 days post vaccination

  3. Safety of BARYCELA inj.: Incidence and severity of unsolicited AEs

    The incidence and severity of unsolicited AEs

    Time frame: during 42 days post vaccination

  4. Safety of BARYCELA inj.: Incidence of adverse event of special interest

    The incidence of AE of Special Interest (AESI): varicella-like rash.

    Time frame: during 42 days post vaccination

  5. Safety of BARYCELA inj.: Vital signs

    Vital signs

    Time frame: Day0(Pre vaccination), 42 days post vaccination

  6. Safety of BARYCELA inj.: Body temperature

    Body temperature; measured according to standard of care and thermometer instructions.

    Time frame: Day0(Pre vaccination), 42 days post vaccination

  7. Safety of BARYCELA inj.: Complete physical examination

    Complete physical examination; performed at Screening/Enrollment (Day 0) and Final Visit(Day 42).

    Time frame: Day0(Pre vaccination), 42 days post vaccination

  8. Safety of BARYCELA inj.: Symptom-directed physical examination

    Symptom-directed physical examination (if any symptoms); performed at other timepoints as indicated to assess changes from Screening

    Time frame: Day0(Pre vaccination), during 42 days post vaccination

Secondary outcomes

  1. Immunogenicity of BARYCELA inj.: Geometric Mean Titer (GMT)

    Geometric Mean Titer (GMT) of antibody titer measured with gpELISA

    Time frame: Prior to IP administration and 42 days post vaccination

  2. Immunogenicity of BARYCELA inj.: Geometric Mean Fold Rise (GMFR)

    Geometric Mean Fold Rise (GMFR)

    Time frame: Prior to IP administration and 42 days post vaccination

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2023; primary completion for Apr 2023, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 23, 2022
StartEst.
Feb 2023
Primary completionEst.
Apr 2023
CompletionEst.
Jun 2023
Last update
Dec 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05664152
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Dec 23, 2022
Start date
Feb 2023 (estimated)
Primary completion
Apr 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Dec 23, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MG1111

Start the discussion